NCT07098403

A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma

A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase Ⅲ Study to Evaluate the Efficacy and Safety of SHR-1905 in Subjects With Severe Uncontrolled Asthma

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 408 (estimated)
• Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a phase III study of SHR-1905 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of SHR-1905 in subjects with severe uncontrolled asthma.

Conditions

• Asthma

Interventions

Type	Name	Description
DRUG	SHR-1905 Injection	SHR-1905 injection.
DRUG	SHR-1905 Placebo Injection	SHR-1905 placebo Injection.

Timeline

• Start date: 2025-09-03
• Primary completion: 2028-01-01
• Completion: 2028-06-01
• First posted: 2025-08-01
• Last updated: 2025-09-09

Locations

1 site across 1 country: China